• 1
    Friedenstein AJ, Piatetzky S, Petrakova KV. Osteogenesis in transplants of BM cells. J Embryol Exp Morphol 1966; 16: 38190.
  • 2
    Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human BM by a novel monoclonal antibody, STRO-1. Blood 1991; 78: 5562.
  • 3
    Anjos-Afonso F, Bonnet D. Nonhemato-poietic/endothelial SSEA-1 + cells define the most primitive progenitors in the adult murine BM mesenchymal compartment. Blood 2007; 109: 1298306.
  • 4
    Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. SSEA-4 identifies mesenchymal stem cells from BM. Blood 2007; 109: 174351.
  • 5
    Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self-renewing osteoprogenitors in BM sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 32436.
  • 6
    Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999; 107: 27581.
  • 7
    Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human BM differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113: 11616.
  • 8
    Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 136077.
  • 9
    Menendez P, Perez-Simon JA, Mateos MV, Caballero MD, Gonzalez M, San Miguel JF, Orfao A. Influence of the different CD34 + and CD34-cell subsets infused on clinical outcome after non-mye-loablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors. Br. J. Haematol 2002; 119: 13543.
  • 10
    Fernández-Miguel G, Bovy T. Production of cell-based medicines for somatic cell therapy. In: D. Garcia-Olmo, J. M. García-Verdugo, J. Alemany, and J. A. Gutiérrez-Funetes, editors. Cell therapy. Madrid : McGraw-Hill/Interamericana de España; 2008. pp. 3341.
  • 11
    Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells are capable of homing to the BM of non-human primates following systemic infusion. Exp Hematol 2001; 29: 24455.
  • 12
    Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic BM-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 89327.
  • 13
    Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 36: 143941.
  • 14
    Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F. Human BM derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67: 91429.
  • 15
    Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S. Accumulated chromosomal instability in murine BM mesenchymal stem cells leads to malignant transformation. Stem Cells 2006; 24: 1095103.
  • 16
    Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 30359.
  • 17
    Cobo F, Navarro JM, Herrera MI, Vivo A, Porcel D, Jurado M, García-Castro J, Menendez P. Electron microscopy reveals the presence of viruses in mouse embryonic fibroblasts but neither in human embryonic fibroblasts nor in human mes-enchymal cells used for hESC maintenance: toward an implementation of microbiological quality assurance program in stem cell banks. Cloning Stem Cells . 2008; 10: 6574.
  • 18
    Menendez P, Wang Bhatia M. Genetic manipulation of human embryonic stem cells: a system to study early human development and potential therapeutic applications. Curr Gene Ther 2005; 5: 37585.
  • 19
    Kon E, Muraglia A, Corsi A, Bianco P, Marcacci M, Martin I, Boyde A, Ruspantini I, Chistolini P, Rocca M, Giardino R, Cancedda R, Quarto R. Autologous BM stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res . 2000; 49: 32837.
  • 20
    Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK. Transplantability and therapeutic effects of BM-derived mesenchymal cells in children with osteogenesis imper-fecta. Nat Med 1999; 5: 30913.
  • 21
    Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchy-mal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 30716.
  • 22
    Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lonnies H, Nava S, Ringden O. Transplantation of mesenchy-mal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21: 17338.
  • 23
    Sykes M. Immune tolerance: mechanisms and application in clinical transplantation. J Intern Med . 2007; 262: 288310.
  • 24
    Singh NJ, Schwartz RH. Primer: mechanisms of immunologic tolerance. Nat Clin Pract Rheumatol 2006; 2: 4452.
  • 25
    Sundrud MS, Rao A. New twists of T cell fate: control of T cell activation and tolerance by TGF-beta and NFAT. Curr Opin Immunol 2007; 19: 28793.
  • 26
    Sohn SJ, Thompson J, Winoto A. Apoptosis during negative selection of autoreactive thymocytes. Curr Opin Immunol . 2007; 19: 5105.
  • 27
    Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol . 2005; 6: 11607.
  • 28
    Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol . 2007; 7: 63343.
  • 29
    Madrenas J, Chau LA, Smith J, Bluestone JA, Germain RN. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med. 1997; 185: 21929.
  • 30
    Tarazona R, Williams O, Moskophidis D, Smyth LA, Tanaka Y, Murdjeva M, Wack A, Mamalaki C, Kioussis D. Susceptibility and resistance to antigen-induced apopto-sis in the thymus of transgenic mice. J Immunol. 1998; 160: 5397403.
  • 31
    Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM. Major histocompat-ibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J Exp Med. 2001; 194: 42738.
  • 32
    Tang Q, Bluestone JA. The Foxp3 + regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008; 9: 23944.
  • 33
    Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nunez G, Tang A, Sayegh M, Hancock WW, Strom TB, Turka LA. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 1999; 5: 13037.
  • 34
    Chau LA, Rohekar S, Wang JJ, Lian D, Chakrabarti S, Zhang L, Zhong R, Madrenas J. Thymic re-entry of mature activated T cells and increased negative selection in vascularized allograft recipients. Clin Exp Immunol 2002; 127: 4352.
  • 35
    Tian C, Bagley J, Lacomini J. Homeostatic expansion permits T cells to re-enter the thymus and deliver antigen in a tolerogenic fashion. Am J Transplant. 2007; 7: 193441.
  • 36
    Reich-Zeliger S, Bachar-Lustig E, Bar-Man A, Reisner Y. Tolerance induction in presensitized BM recipients by veto CTLs: effective deletion of host anti-donor memory effector cells. J Immunol. 2007; 179: 638994.
  • 37
    Madrenas J, Schwartz RH, Germain RN. Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Proc Natl Acad Sci USA . 1996; 93: 973641.
  • 38
    Salojin KV, Zhang J, Madrenas J, Delovitch TL. T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease. Immunol Today . 1998; 19: 46873.
  • 39
    Choi S, Schwartz RH. Molecular mechanisms for adaptive tolerance and other T cell anergy models. Semin Immunol. 2007; 19: 14052.
  • 40
    Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity . 1997; 6: 4117.
  • 41
    Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity . 2001; 14: 14555.
  • 42
    O'Neill HC. Dendritic cell therapy for tolerance induction to stem cell transplants. Curr Stem Cell Res Ther. 2006; 1: 1215.
  • 43
    Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol. 2006; 7: 116673.
  • 44
    Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Rep. 2008; 9: 505.
  • 45
    Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000; 6: 7829.
  • 46
    Zhang ZX, Young K, Zhang L. CD3+CD4-CD8- alphabeta-TCR+ T cell as immune regulatory cell. J Mol Med. 2001; 79: 41927.
  • 47
    Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006; 212: 2850.
  • 48
    Starzl TE. Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med. 2008; 358: 40711.
  • 49
    Roelen D, Brand A, Claas FH. Pretransplant blood transfusions revisited: a role for CD(4+) regulatory T cells? Transplantation . 2004; 77: S268.
  • 50
    Chavers BM, Sullivan EK, Tejani A, Harmon WE. Pre-transplant blood transfusion and renal allograft outcome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant . 1997; 1: 228.
  • 51
    Fandrich F, Lin X, Chai GX, Schulze M, Ganten D, Bader M, Holle J, Huang DS, Parwaresch R, Zavazava N, Binas B. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med. 2002; 8: 1718.
  • 52
    Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, Itskovitz-Eldor J, Reubinoft B, Mandelboim O, Benvenisty N. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA . 2002; 99: 98649.
  • 53
    Menendez P, Bueno C, Wang L, Bhatia M. Human embryonic stem cells: potential tool for achieving immunotolerance?. Stem Cell Rev. 2005; 1: 1518.
  • 54
    Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol . 2003; 31: 8906.
  • 55
    Tuan RS, Boland G, Tuli R. Adult mes-enchymal stem cells and cell-based tissue engineering. Arthritis Res Ther. . 2003; 5: 3245.
  • 56
    Breitbart AS, Grande DA, Mason JM, Barcia M, James T, Grant RT. Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg . 1999; 42: 48895.
  • 57
    Cetrulo CL Jr. Cord-blood mesenchymal stem cells and tissue engineering. Stem Cell Rev . 2006; 2: 1638.
  • 58
    Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-deliv-ery vehicles for anticancer agents. J Natl Cancer Inst . 2004; 96: 1593603.
  • 59
    Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther . 2008; 15: 7308.
  • 60
    Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mes-enchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPSIH). BM Transplant . 2002; 30: 21522.
  • 61
    M̧ller P, Bulnheim U, Diener A, Ļthen F, Teller M, Klinkenberg ED, Neumann HG, Nebe B, Liebold A, Steinhoff G, Rychly J. Calcium phosphate surfaces promote osteogenic differentiation of mesenchymal stem cells. J Cell Mol Med . 2008; 12: 28191.
  • 62
    Marí-Beffa M, Santamaría JA, Murciano C, Santos-Ruiz L, Andrades JA, Guerado E, Becerra J. Zebrafish fins as a model system for skeletal human studies. Sci World J. 2007; 7: 111427.
  • 63
    Karlsson C, Brantsing C, Svensson T, Brisby H, Asp J, Tallheden T, Lindahl A. Differentiation of human mesenchymal stem cells and articular chondrocytes: analysis of chondrogenic potential and expression pattern of differentiation related transcription factors. J Orthop Res . 2007; 25: 15263.
  • 64
    Kurth T, Hedbom E, Shintani N, Sugimoto M, Chen FH, Haspl M, Martinovic S, Hunziker EB. Chondrogenic potential of human synovial mesenchymal stem cells in alginate. Osteoarthritis Cartilage . 2007; 15: 117889.
  • 65
    Mazhari R, Hare JM. Advances in cell-based therapy for structural heart disease. Prog Cardiovasc Dis . 2007; 49: 38795.
  • 66
    Fuster V, Sanz J. Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research. Nat Clin Prac Cardiovas Med . 2007; 4: S18.
  • 67
    Zietlow R, Lane EL, Dunnett SB, Rosser AE. Human stem cells for CNS repair. Cell Tissue Res . 2008; 331: 30122.
  • 68
    Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE . 2008; 3: e188694.
  • 69
    Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JW, Tiemann K, Bohlen H, Hescheler J, Welz A, Bloch W, Jacobsen SE, Fleischmann BK. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood . 2007; 110: 13629.
  • 70
    Darwin J. Prockop, Scott DO. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood . 2007; 109: 314751.
  • 71
    Duncan AW, Rattis FM, DiMascio L, Congdon KL, Pazianos G, Zhao C, Yoon K, Cook JM, Willert K, Gaiano N, Reya T. Integration of Noch and Wnt signalling in hematopoietic stem cell maintenance. Nat Immunol . 2005; 6: 31422.
  • 72
    Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. Tie2/angiopoietic-1 signaling regulates hematopoietic stem cell quiescence in the BM niche. Cell. 2004; 118: 14961.
  • 73
    Li L, Xie T. Stem cell niche: structure and function. Ann Rev Cell Dev Biol . 2005; 21: 60531.
  • 74
    Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the hematopoietic stem cell niche and control of the niche size. Nature . 2003; 425: 83641.
  • 75
    Aggarwal S, Pittenger MF. Human mes-enchymal stem cells modulate allogeneic immune cell responses. Blood . 2005; 105: 181522.
  • 76
    Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. BM mesenchymal stem cells induce division arrest anergy of activated T cells. Blood . 2005; 105: 28217.
  • 77
    Tabera S, Pérez-Simón J, Díez-Campelo M, Sánchez-Abarca L, Blanco B, López A, San Miguel JF. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B lymphocytes. Haematologica . 2008; 93: 13019.
  • 78
    Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unrespon-siveness. Blood . 2005; 105: 22149.
  • 79
    Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood . 2005; 105: 41206.
  • 80
    Stanley RR, Frederick RA. Graft-versus-host disease: a surge of developments. PLoS Medicine . 2007; 4: e198205.
  • 81
    Collins RH, Shpilberg O, Drobyski O, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients relapsed with malignancy after allogeneic BM transplantation. J Clin Oncol . 1997; 15: 43344.
  • 82
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol . 2008; 26: 57784.
  • 83
    Pérez-Simón J, Sureda A, Fernández-Avilés F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosiñol L, Lahuerta J, Díez-Martín JL, León A, García A, Vazquez L, Sierra J, San Miguel JF. Reduced intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia . 2006; 20: 5425.
  • 84
    Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med . 2007; 262: 50925.
  • 85
    Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-ver-sus-host disease. Transplantation . 2006; 81: 13907.
  • 86
    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O. Mesenchymal stem cells for the treatment of steroid resistant, severe, acute graft versus host disease: a phase II study. Lancet . 2008; 371: 157989.
  • 87
    Yãnez R, Lamana M, García-Castro J, Colmenero I, Ramirez M, Buren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells . 2006; 24: 258291.
  • 88
    Fang B, Liao S, Zhang Y, Zhao R. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proceeding . 2007; 39: 335862.
  • 89
    Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu  , Li B, Xu C, Li Y, Wang J, Hu J, Lou X, Chen H. The correlation between cotransplantation of MSC and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical trial. Leukemia . 2008; 22: 5939.
  • 90
    Vianello F, Dazzi F. Mesenchymal stem cells for graft-versus-host disease: a double edge sword? Leukemia . 2008; 22: 4635.
  • 91
    Bueno C, Lopes LF, Menendez P. BM stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32). Blood Cells Mol Dis. 2007; 39: 3668.
  • 92
    Lazarus H, Koc O, Devine S, Curtin P, Maziarz R, Holland H, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mes-enchymal stem cells andhematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant . 2005; 11: 38998.
  • 93
    Villarón EM, Pérez-Simón JA, San Miguel JF, Del Cañizo C. BM mesenchymal stem cells chimerism after allogeneic hematopoietic transplantation. Exp Hematol . 2006; 34: 7.
  • 94
    Ball L, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler R, Locatelli F, Fibbe WE. Co-transplantation of ex-vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem cell transplantation. Blood . 2007; 110: 27647.
  • 95
    Ringdén O, Uzunel M, Sundberg B, Lönnies L, Nava S, Gustafsson J, Henningsohn L, Le Blanc K. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia . 2007; 21: 22716.
  • 96
    Nöth U, Steiner AF, Tuan RS. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheumatol . 2008; 4: 37180.
  • 97
    Tzaribachev N, Vaegler M, Schaefer J, Reize P, Rudert M, Handgretinger Muller I. Mesenchymal stromal cells: a novel treatment option for steroid-induced avas-cular osteonecrosis. Isr Med Assoc J . 2008; 10: 2324.
  • 98
    Richadson S, Hoyland JA. Stem cell regeneration of degenerated intervertebral discs: current status. Curr Pain Headache Rep . 2008; 12: 838.
  • 99
    Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells – old concepts, new insights. Cell Death Differ . 2008; 15: 94758.
  • 100
    Perez-Mancera PA, Sanchez-Garcia I. Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. Semin Cancer Biol . 2005; 15: 20614.
  • 101
    Riggi N, Cironi L, Provero P, Suvà ML, Stehle JC, Baumer K, Guillou L, Stamenkovic I. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res . 2006; 66: 701623.
  • 102
    Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL Jr. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1dependent, ewing sarcoma-like tumors. Cancer Res . 2005; 65: 8698705.
  • 103
    Riggi N, Cironi L, Provero P, Suvà ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I. Development of Ewing's sarcoma from primary BM-derived mesenchymal progenitor cells. Cancer Res 2005; 65: 1145968.
  • 104
    Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC, Baumer K, Kindler V, Stamenkovic I. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008; 68: 217685.
  • 105
    Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, Singer S, Maki RG, Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells viainactivation of the Wnt pathway. J Clin Invest. 2007; 117: 324857.
  • 106
    Matushansky I, Hernando E, Socci ND, Matos T, Mills J, Edgar MA, Schwartz GK, Singer S, Cordon-Cardo C, Maki RG. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol . 2008; 172: 106980.
  • 107
    Serakinci N, Guldberg P, Burns JS, Abdallah B, Schr̄dder H, Jensen T, Kassem M. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene. 2004; 23: 50958.
  • 108
    Shima Y, Okamoto T, Aoyama T, Yasura K, Ishibe T, Nishijo K, Shibata KR, Kohno Y, Fukiage K, Otsuka S, Uejima D, Nakayama T, Nakamura T, Kiyono T, Toguchida J. In vitro transformation of mesenchymal stem cells by oncogenic H-rasVal12. Biochem Biophys Res Commun . 2007; 353: 606.
  • 109
    Liu C, Chen Z, Chen Z, Zhang T, Lu Y. Multiple tumor types may originate from BM-derived cells. Neoplasia . 2006; 8: 71624.
  • 110
    Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from BM-derived cells. Science. 2004; 306: 156871.
  • 111
    Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449: 55763.
  • 112
    Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation . 2006; 82: 10606.
  • 113
    Galie M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, Krampera M, Magnani P, Merigo F, Montani M, Boschi F, Marzola P, Orrù R, Farace P, Sbarbati A, Amici A. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene . 2008; 27: 254251.
  • 114
    Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Rème T, Bourin P. BM mesenchymal stem cells are abnormal in multiple myeloma. Leukemia . 2007; 21: 107988.
  • 115
    Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007; 117: 104957.
  • 116
    Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, Schmoll HJ. Presence of mesenchymal stem cells in human BM after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells. 2006; 24: 275365.
  • 117
    Meads MB, Hazlehurst LA, Dalton WS. The BM microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res . 2008; 14: 251926.
  • 118
    Rubio D, Garcia S, De la Cueva T, Paz MF, Lloyd AC, Bernad A, Garcia-Castro J. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp Cell Res . 2008; 314: 6918.
  • 119
    Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J, McNiece IK. Outgrowth of a transformed cell population derived from normal human BM mes-enchymal stem cell culture. Cytotherapy . 2005; 7: 50919.
  • 120
    Li H, Fan X, Kovi RC, Moquin B, Konz R, Stoicov C, Kurt-Jones E, Grossman SR, Lyle S, Rogers AB, Montrose M, Houghton J. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Res. 2007; 67: 1088998.
  • 121
    Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR. Sarcoma derived from cultured mesenchym al stem cells. Stem Cells. 2007; 25: 3719.
  • 122
    Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res . 2008; 68: 422938.
  • 123
    Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Human BM-derived mesenchy-mal stem cells in the treatment of gliomas. Cancer Res . 2005; 65: 330718.
  • 124
    Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T. Human mes-enchymal stem cells exert potent antitu-morigenic effects in a model of Kaposi's sarcoma. J Exp Med . 2006 15 203: 123547.
  • 125
    Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, Li SF, Long D, Tan WD, Mao YQ, Zhang J, Li YP, Cheng JQ. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther . 2007; 7: 28.
  • 126
    Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L, Zhang X. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res . 2008; 18: 5007.
  • 127
    Hakkarainen T, Sarkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in ortho-topic lung and breast tumors. Hum Gene Ther. 2007; 18: 62741.
  • 128
    Stoff-Khalili MA, Rivera AA, Mathis JM, DeBenedetti A, Li XL, Odaka Y, Podduturi J, Sibley DA, Siegal GP, Stoff A, Young S, Zhu ZB, Curiel DT, Mathis JM. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metas-tases of breast carcinoma. Breast Cancer Res Treat . 2007; 105: 15767.
  • 129
    Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, Barry F, O'Brien T, Zwacka R. Mesenchymal Stem Cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med. 2008 (doi: DOI: 10.1111/j.15824934.2008.00317.x).
  • 130
    Rubio D, Garcia S, Paz MF, De la Cueva T, Lopez-Fernandez LA, Lloyd AC, Garcia-Castro J, Bernad A. Molecular characterization of spontaneous mes-enchymal stem cell transformation. PLoS ONE . 2008; 3: e1398406.
  • 131
    Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol . 2007; 19: 1508.
  • 132
    De Boer J, Wang HJ, Van Blitterswijk C. Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng . 2004; 10: 393401.
  • 133
    Neth P, Ciccarella M, Egea V, Hoelters J, Jochum M, Ries C. Wnt signaling regulates the invasion capacity of human mes-enchymal stem cells. Stem Cells. 2006; 24: 1892903.
  • 134
    Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduc-tion pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev. 2007; 3: 1829.
  • 135
    Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood . 2006; 108: 211420.